1 1

LL-37 (5mg)

LL-37 (5mg)

$65.00 USD
$65.00 USD
Sale Sold out
Shipping calculated at checkout.

Overview:

LL-37 is a 37-amino acid cationic antimicrobial peptide (AMP) derived from the C-terminal portion of the human cathelicidin precursor protein (hCAP18). It plays a central role in innate immunity, functioning as both an antimicrobial effector and an immunomodulator. LL-37 is produced by various cells—including neutrophils, epithelial cells, and macrophages—and is expressed in the skin, lungs, gut, and urinary tract in response to infection or injury.

Beyond its broad-spectrum antimicrobial activity, LL-37 promotes wound healing, angiogenesis, inflammation resolution, and tissue regeneration, making it a promising target for both infectious disease and regenerative medicine.

View full details

COA

Third-Party Testing

What is LL-37?

  • Mechanism of Action:

    LL-37 exerts multifaceted effects through membrane disruption, pattern recognition receptor (PRR) interaction, and intracellular signaling modulation:

    • Disrupts microbial membranes via electrostatic interactions, leading to pathogen lysis
    • Binds to lipopolysaccharides (LPS), neutralizing bacterial endotoxins
    • Modulates immune cell function by activating Toll-like receptors (TLRs) and formyl peptide receptors (FPR2)
    • Stimulates cytokine production, chemotaxis, and dendritic cell maturation
    • Enhances angiogenesis, fibroblast migration, and keratinocyte proliferation for wound repair

  • Preclinical and Clinical Studies:

    Preclinical and Clinical Research:

    • Exhibits broad-spectrum antimicrobial activity against Gram-positive, Gram-negative, fungal, and some viral pathogens
    • Promotes epithelial barrier integrity and accelerates cutaneous wound healing in diabetic and infected wounds
    • Demonstrates anti-biofilm properties against drug-resistant bacteria including Pseudomonas aeruginosa and Staphylococcus aureus
    • Suppresses inflammatory cytokines in models of colitis, psoriasis, and pulmonary inflammation
    • Shown to protect against sepsis, lung injury, and skin infections in animal models
    • In cancer studies, LL-37 displays dual effects—tumor-suppressive in some contexts, pro-tumorigenic in others—depending on the tumor microenvironment

  • Intended Use:

    • The information provided on this site is intended exclusively for educational and research purposes and should not be interpreted as medical guidance.
    • Research compounds, including LL-37, are designed solely for laboratory investigation by qualified professionals and are not intended for human use or consumption.
    • The statements presented here have not been evaluated by the U.S. Food and Drug Administration, and the products discussed are not intended to diagnose, treat, cure, or prevent any disease.